MindWalk names Zachary Maben director of antigen discovery, protein engineering

By Public Technologies
  • MindWalk Holdings named Zachary Maben director of antigen discovery and protein engineering as its pipeline nears preclinical efficacy studies.
  • Maben joins from Arbor Biotechnologies, where he was a principal scientist; he previously held principal and senior scientist roles at Pfizer.
  • Joanne Lim was appointed director of preclinical development, joining from Orum Therapeutics; she previously worked at Codiak Biosciences, Novartis.
  • Shuji Sato, vice president of innovative solutions, expanded responsibilities to include oversight of the pipeline.
  • Sato previously held roles at Dragonfly Therapeutics, Pfizer, Bluefin Biomedicine, Cell Signaling Technology.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MindWalk Holdings Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261014746456) on October 14, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.